Previous 10 | Next 10 |
LEXINGTON, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscul...
Keros Therapeutics (KROS) announces results from a preclinical study of KER-012 on pulmonary and cardiac dysfunction in an established rodent model of pulmonary arterial hypertension ((PAH)) at the virtual American Thoracic Society International Conference held May 14-19. KER-012 prevented ma...
LEXINGTON, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferin...
LEXINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscul...
Keros Therapeutics (KROS): Q1 GAAP EPS of -$0.68 misses by $0.10.Cash and cash equivalents of $255.2MPress Release For further details see: Keros Therapeutics EPS misses by $0.10
LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferin...
Gainers: Brooklyn ImmunoTherapeutics (BTX) +58%.Regional Health Properties (RHE) +49%.Motus GI Holdings (MOTS) +31%.Bel Fuse (BELFB) +29%.Image Sensing Systems (ISNS) +23%.Farmmi (FAMI) +20%.CryoLife (CRY) +18%.Naked Brand (NAKD) +17%.Laureate Education (LAUR) +14%.Insignia Sys...
Gainers: Brooklyn ImmunoTherapeutics (BTX) +38%, Motus GI MOTS +32%, CryoLife (CRY) +16%, Mesoblast MESO +14%, Arcutis Biotherapeutics (ARQT) +10%.Losers: Ardelyx (ARDX) -13%, Pacific Biosciences of California (PACB) -13%, ALX Oncolo...
Keros Therapeutics (KROS): Q4 GAAP EPS of -$0.49 beats by $0.08.Cash and cash equivalents of $265.88M.Press Release For further details see: Keros Therapeutics EPS beats by $0.08
LEXINGTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffer...
News, Short Squeeze, Breakout and More Instantly...
Keros Therapeutics Inc. Company Name:
KROS Stock Symbol:
NASDAQ Market:
Keros Therapeutics Inc. Website:
2024-06-25 22:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-24 17:15:02 ET Oppenheimer analyst issues OUTPERFORM recommendation for KROS on June 24, 2024 04:14PM ET. KROS was trading at $46.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recomme...
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patie...